289 lines
8.9 KiB
Markdown
289 lines
8.9 KiB
Markdown
|
|
# Standard Operating Procedure: IRB Protocol Submission and Review
|
||
|
|
|
||
|
|
| Document ID | SOP-IRB-001 |
|
||
|
|
|-------------|-------------|
|
||
|
|
| Title | IRB Protocol Submission and Initial Review Process |
|
||
|
|
| Revision | 1.0 |
|
||
|
|
| Effective Date | [DATE] |
|
||
|
|
| Author | [AUTHOR] |
|
||
|
|
| Approved By | [APPROVER] |
|
||
|
|
| Department | Institutional Review Board |
|
||
|
|
|
||
|
|
---
|
||
|
|
|
||
|
|
## 1. Purpose
|
||
|
|
|
||
|
|
To establish standardized procedures for the submission, review, and approval of human subjects research protocols in accordance with federal regulations (45 CFR 46, 21 CFR 50/56) and institutional policies.
|
||
|
|
|
||
|
|
## 2. Scope
|
||
|
|
|
||
|
|
This procedure applies to all research involving human subjects requiring IRB review, including:
|
||
|
|
- Biomedical research
|
||
|
|
- Behavioral research
|
||
|
|
- Social science research
|
||
|
|
- Educational research
|
||
|
|
- FDA-regulated research (drugs, devices, biologics)
|
||
|
|
- Exempt, expedited, and full board reviews
|
||
|
|
|
||
|
|
## 3. Responsibilities
|
||
|
|
|
||
|
|
### 3.1 Principal Investigator (PI)
|
||
|
|
- Prepare and submit complete protocol application
|
||
|
|
- Ensure research team training compliance
|
||
|
|
- Respond to IRB stipulations
|
||
|
|
- Maintain protocol compliance
|
||
|
|
|
||
|
|
### 3.2 IRB Coordinator
|
||
|
|
- Process submissions for completeness
|
||
|
|
- Assign review pathway
|
||
|
|
- Coordinate reviewer assignments
|
||
|
|
- Track submission timelines
|
||
|
|
- Communicate decisions
|
||
|
|
|
||
|
|
### 3.3 IRB Chair/Vice Chair
|
||
|
|
- Conduct expedited reviews
|
||
|
|
- Prepare agenda for full board
|
||
|
|
- Sign approval letters
|
||
|
|
- Address urgent matters
|
||
|
|
|
||
|
|
### 3.4 IRB Members
|
||
|
|
- Review assigned protocols
|
||
|
|
- Participate in convened meetings
|
||
|
|
- Vote on protocol actions
|
||
|
|
- Maintain confidentiality
|
||
|
|
|
||
|
|
## 4. Definitions
|
||
|
|
|
||
|
|
| Term | Definition |
|
||
|
|
|------|------------|
|
||
|
|
| Common Rule | Federal Policy for the Protection of Human Subjects (45 CFR 46) |
|
||
|
|
| Exempt | Research meeting criteria that does not require ongoing IRB oversight |
|
||
|
|
| Expedited | Minimal risk research eligible for review outside convened meeting |
|
||
|
|
| Full Board | Research requiring review at convened IRB meeting |
|
||
|
|
| Minimal Risk | Risk no greater than encountered in daily life |
|
||
|
|
|
||
|
|
## 5. Procedure
|
||
|
|
|
||
|
|
### 5.1 Pre-Submission Requirements
|
||
|
|
|
||
|
|
Before submission, PI must ensure:
|
||
|
|
- [ ] All study personnel have completed required training (CITI, GCP)
|
||
|
|
- [ ] Training certificates uploaded to protocol file
|
||
|
|
- [ ] Conflict of interest disclosures current
|
||
|
|
- [ ] Department/division approval obtained (if required)
|
||
|
|
- [ ] Funding information available
|
||
|
|
- [ ] Study documents prepared (protocol, consent, recruitment materials)
|
||
|
|
|
||
|
|
### 5.2 Protocol Submission
|
||
|
|
|
||
|
|
#### 5.2.1 Required Application Components
|
||
|
|
|
||
|
|
| Document | Required for All | Notes |
|
||
|
|
|----------|------------------|-------|
|
||
|
|
| Protocol application form | ☐ | Complete all sections |
|
||
|
|
| Research protocol/plan | ☐ | Detailed methods |
|
||
|
|
| Informed consent form(s) | ☐ | Unless waiver requested |
|
||
|
|
| Recruitment materials | If applicable | Flyers, scripts, ads |
|
||
|
|
| Data collection instruments | ☐ | Surveys, questionnaires |
|
||
|
|
| Investigator brochure | FDA-regulated | Drug/device studies |
|
||
|
|
| Grant/funding documents | If externally funded | |
|
||
|
|
| Training documentation | ☐ | All personnel |
|
||
|
|
| COI disclosures | ☐ | All personnel |
|
||
|
|
| Site authorization letters | Multi-site | External sites |
|
||
|
|
| Translations | Non-English | Consent, materials |
|
||
|
|
|
||
|
|
#### 5.2.2 Submission Process
|
||
|
|
1. Complete application in electronic system
|
||
|
|
2. Upload all required documents
|
||
|
|
3. Obtain department approval routing
|
||
|
|
4. Submit to IRB
|
||
|
|
|
||
|
|
### 5.3 Administrative Review
|
||
|
|
|
||
|
|
IRB staff conducts administrative review within **3 business days**:
|
||
|
|
|
||
|
|
| Check | Action |
|
||
|
|
|-------|--------|
|
||
|
|
| Application completeness | Return if incomplete |
|
||
|
|
| Required documents attached | Request missing items |
|
||
|
|
| Training current | Verify certificates |
|
||
|
|
| COI disclosures filed | Confirm compliance |
|
||
|
|
| Regulatory pathway | Assign review category |
|
||
|
|
|
||
|
|
### 5.4 Review Categories
|
||
|
|
|
||
|
|
#### 5.4.1 Exempt Determination
|
||
|
|
|
||
|
|
Research may qualify for exemption under 45 CFR 46.104 categories:
|
||
|
|
1. Educational settings research
|
||
|
|
2. Surveys, interviews, observation (with limitations)
|
||
|
|
3. Benign behavioral interventions
|
||
|
|
4. Secondary research with identifiable data
|
||
|
|
5. Federal program evaluation
|
||
|
|
6. Taste/food quality studies
|
||
|
|
7. Storage or maintenance of specimens/data
|
||
|
|
8. Secondary research for regulatory purposes
|
||
|
|
|
||
|
|
**Process:**
|
||
|
|
- IRB staff or designated reviewer conducts exemption determination
|
||
|
|
- Timeline: 5 business days
|
||
|
|
- Outcome: Exempt letter or escalation to expedited/full review
|
||
|
|
|
||
|
|
#### 5.4.2 Expedited Review
|
||
|
|
|
||
|
|
Eligible for expedited if:
|
||
|
|
- Minimal risk, AND
|
||
|
|
- Falls into expedited categories (45 CFR 46.110)
|
||
|
|
|
||
|
|
**Expedited Categories include:**
|
||
|
|
1. Clinical studies of approved products
|
||
|
|
2. Collection of blood samples
|
||
|
|
3. Prospective collection of specimens (non-invasive)
|
||
|
|
4. Data collection through non-invasive procedures
|
||
|
|
5. Research on characteristics/behavior
|
||
|
|
6. Voice, video, image recording for research
|
||
|
|
7. Study of existing data/specimens
|
||
|
|
8. Continuing review (specific conditions)
|
||
|
|
9. Minor changes to approved research
|
||
|
|
|
||
|
|
**Process:**
|
||
|
|
- Assigned to IRB Chair/Vice Chair or experienced member
|
||
|
|
- Timeline: 10 business days
|
||
|
|
- Outcomes: Approve, require modifications, refer to full board
|
||
|
|
|
||
|
|
#### 5.4.3 Full Board Review
|
||
|
|
|
||
|
|
Required when:
|
||
|
|
- Greater than minimal risk, OR
|
||
|
|
- Not eligible for expedited categories, OR
|
||
|
|
- Involves vulnerable populations with complex issues
|
||
|
|
|
||
|
|
**Process:**
|
||
|
|
- Assigned primary reviewer(s)
|
||
|
|
- Placed on meeting agenda
|
||
|
|
- Quorum required for deliberation
|
||
|
|
- Outcomes: Approve, modifications required, table, disapprove
|
||
|
|
|
||
|
|
### 5.5 Review Criteria
|
||
|
|
|
||
|
|
IRB must determine that all of the following are satisfied:
|
||
|
|
|
||
|
|
| Criterion | Requirement |
|
||
|
|
|-----------|-------------|
|
||
|
|
| Risks minimized | Through sound design, existing procedures when possible |
|
||
|
|
| Risks reasonable | In relation to anticipated benefits |
|
||
|
|
| Equitable selection | Of subjects, including vulnerable populations |
|
||
|
|
| Informed consent | Sought and documented appropriately |
|
||
|
|
| Data safety | Adequate provisions for monitoring |
|
||
|
|
| Privacy/confidentiality | Adequate protections in place |
|
||
|
|
| Vulnerable populations | Additional safeguards when appropriate |
|
||
|
|
|
||
|
|
### 5.6 Informed Consent Evaluation
|
||
|
|
|
||
|
|
#### Required Elements of Consent (45 CFR 46.116)
|
||
|
|
- [ ] Statement that study involves research
|
||
|
|
- [ ] Explanation of purposes
|
||
|
|
- [ ] Expected duration of participation
|
||
|
|
- [ ] Description of procedures
|
||
|
|
- [ ] Description of reasonably foreseeable risks
|
||
|
|
- [ ] Description of benefits
|
||
|
|
- [ ] Alternative procedures or treatments
|
||
|
|
- [ ] Confidentiality protections
|
||
|
|
- [ ] Compensation/treatment for injury (if applicable)
|
||
|
|
- [ ] Contact information
|
||
|
|
- [ ] Statement that participation is voluntary
|
||
|
|
|
||
|
|
#### Additional Elements (as applicable)
|
||
|
|
- [ ] Unforeseeable risks
|
||
|
|
- [ ] Circumstances for termination
|
||
|
|
- [ ] Additional costs to subject
|
||
|
|
- [ ] Consequences of withdrawal
|
||
|
|
- [ ] Significant new findings disclosed
|
||
|
|
- [ ] Number of subjects
|
||
|
|
- [ ] Biospecimen commercial use statement
|
||
|
|
- [ ] Whole genome sequencing statement
|
||
|
|
|
||
|
|
### 5.7 IRB Meeting Procedures
|
||
|
|
|
||
|
|
1. **Quorum Requirements**
|
||
|
|
- Majority of members
|
||
|
|
- At least one non-scientist
|
||
|
|
- Scientific expertise relevant to studies reviewed
|
||
|
|
|
||
|
|
2. **Meeting Process**
|
||
|
|
- Primary reviewer presents protocol
|
||
|
|
- Discussion by members
|
||
|
|
- PI may be invited for questions
|
||
|
|
- Deliberation (PI excused)
|
||
|
|
- Vote by show of hands
|
||
|
|
|
||
|
|
3. **Voting Actions**
|
||
|
|
| Action | Definition |
|
||
|
|
|--------|------------|
|
||
|
|
| Approved | Ready to proceed |
|
||
|
|
| Approved with modifications | Minor changes required (verified by Chair) |
|
||
|
|
| Tabled | Substantive concerns requiring major revision |
|
||
|
|
| Disapproved | Criteria not met, does not meet regulatory requirements |
|
||
|
|
|
||
|
|
### 5.8 Post-Review Communication
|
||
|
|
|
||
|
|
1. **Approval Letter**
|
||
|
|
Includes:
|
||
|
|
- Approval date
|
||
|
|
- Expiration date (if applicable)
|
||
|
|
- Approved documents and versions
|
||
|
|
- Approval conditions
|
||
|
|
- Continuing review requirements
|
||
|
|
|
||
|
|
2. **Modifications Required Letter**
|
||
|
|
- Specific changes requested
|
||
|
|
- Timeline for response
|
||
|
|
- Process for resubmission
|
||
|
|
|
||
|
|
3. **Disapproval Letter**
|
||
|
|
- Reasons for disapproval
|
||
|
|
- Right to respond/appeal
|
||
|
|
|
||
|
|
### 5.9 Response to Stipulations
|
||
|
|
|
||
|
|
1. PI submits written response addressing each stipulation
|
||
|
|
2. Revise documents as requested
|
||
|
|
3. Upload revised materials
|
||
|
|
4. Chair/reviewer verifies adequacy
|
||
|
|
5. Final approval issued when complete
|
||
|
|
|
||
|
|
## 6. Timelines
|
||
|
|
|
||
|
|
| Review Type | Target Timeline |
|
||
|
|
|-------------|-----------------|
|
||
|
|
| Administrative review | 3 business days |
|
||
|
|
| Exempt determination | 5 business days |
|
||
|
|
| Expedited review | 10 business days |
|
||
|
|
| Full board (to meeting) | Next scheduled meeting |
|
||
|
|
| Post-meeting stipulations | 10 business days after response |
|
||
|
|
|
||
|
|
## 7. Documentation
|
||
|
|
|
||
|
|
- FRM-IRB-001 Protocol Submission Form
|
||
|
|
- FRM-IRB-002 Informed Consent Template
|
||
|
|
- FRM-IRB-003 Reviewer Checklist
|
||
|
|
- Meeting minutes
|
||
|
|
- Approval/action letters
|
||
|
|
- Correspondence log
|
||
|
|
|
||
|
|
## 8. References
|
||
|
|
|
||
|
|
- 45 CFR 46 - Protection of Human Subjects
|
||
|
|
- 21 CFR 50 - Protection of Human Subjects (FDA)
|
||
|
|
- 21 CFR 56 - Institutional Review Boards (FDA)
|
||
|
|
- OHRP Guidance Documents
|
||
|
|
- ICH E6 Good Clinical Practice
|
||
|
|
|
||
|
|
---
|
||
|
|
|
||
|
|
## Revision History
|
||
|
|
|
||
|
|
| Rev | Date | Description | Author |
|
||
|
|
|-----|------|-------------|--------|
|
||
|
|
| 1.0 | [DATE] | Initial release | [AUTHOR] |
|